Figure 5.

Effect of FAP inhibition on liver/spleen weight and general liver inflammation in Mdr2−/− mice. (A), Scheme of FVB control and Mdr2−/− biliary fibrotic mice (n = 5 and n = 10 mice per group, respectively) treated with FAPi (15 or 50 mg/kg bw) or vehicle for 2 weeks. (B−C), Liver/bw ratio and spleen/bw ratio. (D), Representative images of H&E staining from liver sections. (E−H), Serum ALT, AST, ALP, and creatinine levels. Data in (B−C, E−H) are means ± standard errors of the mean (SEMs). Statistical analysis was performed as for Figure 1.